### Diffuse Large B-Cell Lymphoma (BCEL)

<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **BCEL-C 2 of 4 and HGBL-1**  
 **Internal request**  
 In response to the FDA approval of bendamustine, rituximab and polatuzumab vedotin-piiq for the treatment of relapsed or refractory DLBCL, the panel voted on the addition of this regimen. | Based upon the FDA approval and the noted reference, the panel consensus was to include bendamustine, rituximab and polatuzumab vedotin-piiq as an option with category 2A recommendation for the following indications:  
- Relapsed/refractory DLBCL in non-candidates for transplant (after ≥ 2 prior therapies)  
- Relapsed/refractory high-grade B-cell lymphomas with translocations of MYC and BCL2 and/or BCL6 (Double/Triple Hit Lymphoma) in non-candidates for transplant (after ≥ 2 prior therapies) | YES | NO | ABSTAIN | ABSENT |
| **Sehn LH, Herrera AF, Matasar MJ, et al.**  
 Polatuzumab vedotin (Pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated results of a phase (Ph) Ib/II study [abstract]. Blood 2018;132: Abstract 1683. |                                                                 | 19 | 0 | 1 | 8 |
|  |                                                                 | 17 | 2 | 1 | 8 |
| **External request**  
 Submission request from Genentech to consider inclusion of polatuzumab vedotin in combination with BR as a treatment option for “Second-line and Subsequent Therapy” in patients with relapsed or refractory DLBCL (BCEL-C 2 of 4). | Sehn LH, Herrera AF, Matasar MJ, et al. Polatuzumab vedotin (Pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated results of a phase (Ph) Ib/II study [abstract]. Blood 2018;132: Abstract 1683. | 11 | 8 | 1 | 8 |
| **BCEL-C 2 of 4**  
 **Internal request**  
 Comment to reassess the inclusion of bendamustine ± rituximab as a relapsed/refractory DLBCL in non-candidates for transplant. | Based on the data in the noted reference, the panel consensus was for bendamustine ± rituximab to remain an option with a category designation change from a category 2A to category 2B.  
 Sehn LH, Herrera AF, Matasar MJ, et al. Polatuzumab vedotin (Pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated results of a phase (Ph) Ib/II study [abstract]. Blood 2018;132: Abstract 1683. | 11 | 8 | 1 | 8 |